Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo
Oral mucositis (any severity) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
4 findings from 1 review
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesBMT/SCT after conditioning for haematological cancersRR 0.96 [0.88, 1.05]4 studies · 655 participantsGRADE not reported
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesChildrenTwo studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented2 studiesGRADE not reported
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesRT to head and neck with cisplatin/fluorouracilRR 0.95 [0.90, 1.00]2 studies · 374 participantsGRADE not reported
Show 1 more finding
- Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomesChemotherapy alone for mixed cancersRR 0.71 [0.60, 0.85]2 studies · 215 participantsGRADE not reported